Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model

The Renal sodium-dependent glucose co-transporter 2 (SGLT2) is one of the most promising targets for the treatment of type 2 diabetes. Two SGLT2 inhibitors, dapagliflozin, and canagliflozin, have already been approved for use in USA and Europe; several additional compounds are also being developed f...

Descripción completa

Detalles Bibliográficos
Autores principales: Demin, Oleg, Yakovleva, Tatiana, Kolobkov, Dmitry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195280/
https://www.ncbi.nlm.nih.gov/pubmed/25352807
http://dx.doi.org/10.3389/fphar.2014.00218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195280/
https://www.ncbi.nlm.nih.gov/pubmed/25352807
http://dx.doi.org/10.3389/fphar.2014.00218

Ejemplares similares